MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on April 21, 2008; DOI: 10.1124/mol.107.040162


0026-895X/08/7401-70-81$20.00
Mol Pharmacol 74:70-81, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.040162v1
74/1/70    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Cho, H.
Right arrow Articles by Yang, E. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cho, H.
Right arrow Articles by Yang, E. G.

Baicalein Induces Functional Hypoxia-Inducible Factor-1{alpha} and AngiogenesisFormula

Hyunju Cho, Ho-Youl Lee, Dae-Ro Ahn, Sang Yoon Kim, Sunyun Kim, Keun Byeol Lee, You Mie Lee, Hyunsung Park, and Eun Gyeong Yang

Life Sciences Research Division, Korea Institute of Science and Technology, Seoul, Korea (H.C., D.-R.A., S.Y.K., S.K., E.G.Y.); Department of Life Science, University of Seoul, Seoul, Korea (H.-Y.L., H.P.); and Department of Natural Sciences, Kyungpook National University, Daegu, Korea (K.B.L., Y.M.L.)

Targeting the oxygen-sensing mechanisms of the hypoxiainducible factor (HIF) pathway provides pharmacological ways of manipulating the HIF response. Because HIF-1{alpha}-specific prolyl-4 hydroxylases (PHDs) prime degradation of HIF-1{alpha}, we have made an effort to find a small molecule capable of up-regulating the HIF pathway by inhibiting prolyl hydroxylation. Through an in vitro high-throughput screen, we have discovered a PHD2 inhibitor baicalein, which is also found to abrogate asparaginyl hydroxylation of HIF-1{alpha}. Such inhibitory effects are reversed by the addition of excess 2-oxoglutarate and iron(II), suggesting the involvement of baicalein's binding at the enzyme active sites, which has also been corroborated by spectroscopic binding assays between baicalein and enzyme. In addition, baicalein suppresses ubiquitination of HIF-1{alpha}, which works in concert with the inhibition of the HIF-specific hydroxylases to increase the HIF-1{alpha} content, leading to induction of HIF-1-mediated reporter gene activity and target gene transcription in tissue culture cells, whereas it induces HIF-independent activation of other genes. Furthermore, in vivo organ models based on the chick chorioallantoic membrane assay demonstrate that baicalein promotes new blood vessel formation. Together, our results indicate that baicalein possesses a proangiogenic potential and thus might have the therapeutic utility in the treatment of ischemic diseases.


Received July 19, 2007; accepted April 21, 2008

Address correspondence to: Dr. Eun Gyeong Yang, Life Sciences Division, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791, Korea. E-mail: eunyang{at}kist.re.kr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics